TRVI — Trevi Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $191.71m
- $108.89m
- 53
- 25
- 64
- 45
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -26.1 | -32.8 | -33.9 | -29.2 | -29.1 |
Depreciation | |||||
Non-Cash Items | 1.34 | 2.65 | 3.44 | 2.17 | 1.08 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.58 | 1.06 | 1.51 | -1.23 | -3.85 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -23.1 | -29 | -28.9 | -28.2 | -31.7 |
Capital Expenditures | -0.009 | -0.032 | 0 | -0.159 | -0.137 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | — | -107 | 59.6 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.009 | -0.032 | 0 | -107 | 59.4 |
Financing Cash Flow Items | 12.1 | 2.69 | 7.09 | -0.191 | 1.52 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 73.2 | 16.7 | 20.8 | 111 | -7.91 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 50.1 | -12.3 | -8.17 | -24.2 | 19.8 |